Quidel Corporation

Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction

Retrieved on: 
Monday, May 16, 2022
Food, U.S. Securities and Exchange Commission, Antibody, Press release, Lists of disasters, Blood, YouTube, Securities Act of 1933, England, Twitter, Director, Laboratory, United, Certification, COVID-19, Failure, Food and Drug Administration, Facebook, Youth justice in England and Wales, Government, Board, Hospital, Acquisition, Growth, GLOBE, Company, Insurance, IVD, Health, Defense, Ownership, Efficiency, Organization, LinkedIn, Securities Exchange Act of 1934, HIV, Security (finance), Data management, Risk, BCA, Nasdaq, Patient, NASDAQ, High Court, Hepatitis C, Privacy, Intellectual property, Forward-looking statement, Compliance, Safety, Union, Board of directors, Sumathi Best Television Current Reporting Award, Quidel Corporation, Ortho

RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (Ortho or the Company), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (Quidel) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the BCA).

Key Points: 
  • RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (Ortho or the Company), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (Quidel) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the BCA).
  • We have greatly appreciated the opportunity to engage in a thoughtful and constructive dialogue with our shareholders throughout this process.
  • We believe the combination of Quidel and Ortho will be well-positioned to accelerate growth through a broader commercial channel, stronger R&D capabilities, enhanced brand recognition, and wider overall reach by combining Quidel and Orthos complementary, world-class products.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies.

Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination

Retrieved on: 
Monday, May 16, 2022
Technology, Medical Devices, Infectious Diseases, Other Technology, Biotechnology, Other Health, Health, General Health, Data Management, Part, Telephone, Form, Takeover, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, SVC, Corporation, Nasdaq, City Code on Takeovers and Mergers, Infection, Patient, Topco, High Court, SEC filing, Mergers and acquisitions, Nature, Commission, COVID-19, Failure, FDA, UK, TO, Youth justice in England and Wales, Court, Attention, Communication, Terminology, THE, Linear code, England, Acquisition, Security (finance), JOINT, Annual report, Risk management, Quidel Corporation, Ortho

Quidel Corporation (Nasdaq: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (Ortho) by Quidel and subsequent business combination were approved by Quidels stockholders at Quidels Special Meeting on May 16, 2022.

Key Points: 
  • Quidel Corporation (Nasdaq: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (Ortho) by Quidel and subsequent business combination were approved by Quidels stockholders at Quidels Special Meeting on May 16, 2022.
  • Under the terms of the agreement by which Quidel will acquire Ortho, Ortho shareholders will receive $7.14 in cash and 0.1055 shares of the combined company common stock for each Ortho common share.
  • In connection with the proposed business combination transaction among Quidel, Ortho and Coronado Topco, Inc. (Topco), Topco has filed a registration statement on Form S-4 (File No.
  • Each of Quidel and Ortho commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Quidel and Ortho, respectively, on or about April 11, 2022.

vybe urgent care Announces its 14th Greater Philadelphia Location - PCOM

Retrieved on: 
Monday, May 16, 2022
Urgent Care Association, Physician, Blue Bell, Education, Applied behavior analysis, Quidel Corporation, Osteopathy, Population, Wynnefield Heights, Philadelphia, U.S. Route 1 in Pennsylvania, Forensic medicine, Leadership, Patient, Health promotion, Insurance, PCOM, Medical laboratory scientist, Pharmacy, UCA, Research, DO, Occupational medicine, Partnership, Telehealth, Philadelphia College of Osteopathic Medicine, Student, Instagram, Jewish Healthcare Center (Worcester), Safety, Travel, Abington Township, Montgomery County, Pennsylvania, Colorado EKG Repository, Spring Garden, Bucks, Twitter, COVID, Osteopathic medicine in the United States, Vybe Beatz, Hospital, Moderna, Delaware Valley, Facebook

PHILADELPHIA, May 16, 2022 /PRNewswire/ -- vybe urgent care, the leading independent operator of urgent care centers in the Greater Philadelphia area, announces the opening of a new center on the campus of Philadelphia College of Osteopathic Medicine (PCOM) located at 4190 City Avenue, Philadelphia, PA 19131. The center is open from 8:00 a.m. to 8:00 p.m. Monday through Friday and will be opening for weekend hours in the near future. 

Key Points: 
  • PHILADELPHIA, May 16, 2022 /PRNewswire/ -- vybe urgent care, the leading independent operator of urgent care centers in the Greater Philadelphia area, announces the opening of a new center on the campus of Philadelphia College of Osteopathic Medicine (PCOM) located at 4190 City Avenue, Philadelphia, PA 19131.
  • "We look forward to serving the healthcare needs of this area of the city and to promoting learning opportunities for PCOM students," said vybe urgent care President Peter Hotz.
  • The PCOM location joins vybe's urgent care centers located in Bensalem, Blue Bell, Center City, Center City East, Havertown, Northeast Philadelphia, Port Richmond, Ridley, Roxborough, South Philadelphia, Spring Garden, University City and West Philadelphia.
  • vybe urgent care is Philadelphia's leading independent urgent care provider delivering care to adults and children in Philadelphia, Delaware, Bucks and Montgomery Counties.

Global Molecular Point of Care (POC) Markets and Future Potential Report 2022-2026: Market Sizing, Forecasting, Trend Mapping and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 5, 2022
Infectious Diseases, Health, Medical Supplies, COVID-19, Roche, DNA, PCR, Abbott, Forecasting, POC, IVD, RNA, Market, Pharmaceutical industry, Quidel Corporation

The "The Market and Future Potential for Molecular Point of Care (POC), 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market and Future Potential for Molecular Point of Care (POC), 2022" report has been added to ResearchAndMarkets.com's offering.
  • The Market and Future Potential for Molecular Point of Care (POC), 2022 provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
  • Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems.
  • Molecular Point of Care Market, 2021-2026
    Where is Molecular Point of Care in 2021?

Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022

Retrieved on: 
Wednesday, April 20, 2022
Ortho Clinical Diagnostics, Quidel Corporation, Hepatitis C, COVID-19, Twitter, Blood, Interest, Food, Hospital, YouTube, GLOBE, Patient, Ortho, LinkedIn, IVD, Efficiency, Conference, Health, Nasdaq, Food and Drug Administration, Laboratory, Webcast, Facebook, Antibody, HIV, Medical device, Pharmaceutical industry

RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.

Key Points: 
  • RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.
  • Ortho Clinical Diagnostics will hold a conference call the same day at 4:30 pm ET to discuss the results.
  • Interested parties can access the call and accompanying presentation on the Investors portion of the Companys website at https://ir.orthoclinicaldiagnostics.com/ .
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Global Point of Care & Rapid Diagnostics Market Analysis Report 2022 - Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 19, 2022
Medical Supplies, Health, Hospitals, Other Health, Managed Care, General Health, Quidel Corporation, Awareness, Government, Lists of countries and territories, Adoption, Roche Diagnostics, Long-term care, Conditional sentence, COVID-19, Point-of-care testing, Diabetes, Hospital, CAGR, Infection, OTC, Care, Growth, Dickinson, Danaher Corporation, Abbott Laboratories, Becton, Pregnancy, Laboratory, Glucose, Pharmacy, POCT, Investment, Microfluidics, USD, POC, Prevalence, HIV, Vaccine, Pharmaceutical industry, Medical device, Healthcare

The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.

Key Points: 
  • The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.
  • In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market.
  • The Lateral Flow Assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2021
    Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics.
  • As of 2020, the point of care diagnostics market is dominated by Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Quidel Corporation (US).

Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022

Retrieved on: 
Tuesday, April 12, 2022
Infectious Diseases, Biotechnology, Health, Medical Devices, NASDAQ, Infection, Corporation, FDA, Nasdaq, Telephone, Patient, Investor relations, COVID-19, Webcast, Quidel Corporation

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022.

Key Points: 
  • Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022.
  • Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions.
  • During the conference call, the company will also discuss business and financial developments and trends.
  • The company's statements may contain or constitute material information that has not been previously disclosed.

Quidel Announces Preliminary Revenue for First Quarter 2022

Retrieved on: 
Thursday, April 7, 2022
Biotechnology, General Health, Medical Devices, Infectious Diseases, Health, Private Securities Litigation Reform Act, City Code on Takeovers and Mergers, England, Youth justice in England and Wales, Linear code, NASDAQ, Form, Dangerous, Growth, Attention, Patient, Compliance, Takeover, Ownership, High Court, Commission, Corporation, Reading, Telephone, Failure, Food, U.S. Securities and Exchange Commission, Government, JOINT, Security (finance), THE, TO, Form S-4, Nasdaq, COVID-19, Tax, Regulation of tobacco by the U.S. Food and Drug Administration, Physician, Information technology, Mergers and acquisitions, Nature, Ortho, FDA, Terminology, SVC, Acquisition, Emergency Use Authorization, Infection, Pharmaceutical industry, Risk management, Quidel Corporation

COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue COVID-19 test revenue and approximately $138 million in Sofia SARS antigen test revenue.

Key Points: 
  • COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue COVID-19 test revenue and approximately $138 million in Sofia SARS antigen test revenue.
  • We had another outstanding quarter and an excellent start to the year, delivering a record quarter for revenue, said Douglas Bryant, President and Chief Executive Officer of Quidel.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended March 31, 2022.
  • Quidel expects to issue full financial results for the first quarter of 2022 in May.

Sherlock Biosciences Appoints Karen Davies as Chief Development Officer

Retrieved on: 
Thursday, April 7, 2022
Gen-Probe, Organization, Electronic flight instrument system, PCR, Business transformation, Mechanical, Cancer, Precision medicine, CEO, Population health, Industry, Technology, Biology, Infection, Architecture, Engineering, Sherlock, Stanford University, Mechanical engineering, CRISPR, FDA, History, Management, Quidel Corporation

BOSTON, April 7, 2022 /PRNewswire/ -- Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced that industry veteran Karen Davies has been appointed to its executive team as Chief Development Officer. In her new role at Sherlock Biosciences, Davies will serve as a member of the company's executive leadership team and will lead product development, reporting to Bryan Dechairo, President and CEO of Sherlock Biosciences.

Key Points: 
  • BOSTON, April 7, 2022 /PRNewswire/ -- Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced that industry veteran Karen Davies has been appointed to its executive team as Chief Development Officer.
  • In her new role at Sherlock Biosciences, Davies will serve as a member of the company's executive leadership team and will lead product development, reporting to Bryan Dechairo, President and CEO of Sherlock Biosciences.
  • Karen joins Sherlock with more than 30 years of medical diagnostics and device development experience, honed at organizations including Gen-Probe, Abbott, Dura Pharmaceuticals and Quidel.
  • Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions.

Point of Care and Rapid Diagnostics Market worth $72.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 4, 2022
Adoption, Long-term care, CAGR, Pharmacy, Microfluidics, Conditional sentence, Investment, Diabetes, Growth, Dickinson, Pregnancy, Quidel Corporation, Hospital, Pressure, Power-on self-test, Prevalence, Government, POC, Abbott Laboratories, COVID-19, Physician, Rapid diagnostic test, Infection, Danaher Corporation, Awareness, OTC, Becton, Roche Diagnostics, Pharmaceutical industry, Medical device, Healthcare

In 2021, the glucose monitoring products segment accounted for the largest share of the Rapid Diagnostics Market.

Key Points: 
  • In 2021, the glucose monitoring products segment accounted for the largest share of the Rapid Diagnostics Market.
  • The Lateral Flow Assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2021
    Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics.
  • The global point of care diagnostics market is segmented intoNorth America(comprising the US andCanada),Europe(includesGermany,France, and the UK), theAsia Pacific(includesJapan,China,India),Latin America(Brazil,Mexico), and theMiddle East&Africa.
  • As of 2020, the point of care diagnostics market is dominated by Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Quidel Corporation (US).